You are here

Medical Countermeasure Development for Viral Induced Encephalitis Using Single DomainAntibodies

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911QY-18-C-0004
Agency Tracking Number: C2-0483
Amount: $499,999.05
Phase: Phase II
Program: SBIR
Solicitation Topic Code: CBD161-004
Solicitation Number: 2016.1
Solicitation Year: 2016
Award Year: 2018
Award Start Date (Proposal Award Date): 2017-11-15
Award End Date (Contract End Date): 2019-11-14
Small Business Information
321 Jones Boulevard
Pottstown, PA 19464
United States
DUNS: 962964990
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Rolf Swoboda, PhD
 (610) 990-7531
Business Contact
 Hiep Tran
Phone: (610) 990-7531
Research Institution

Alphaviruses, infection with which may cause encephalitis and death, are recognized as potential biological warfare agents. There are noapproved medical countermeasures against Alphaviruses. In Phase I, using Abzymes proprietary in vivo Self-Diversifying Camelid SingleDomain Antibody Library (SDALib) platform, broadly reactive single domain camelid VHH antibodies against equine encephalitis viral (EEV)protein E3E2 and VHH antibodies against human transferrin receptor TfR were isolated. Isolated EEV E3E2/E2 and TfR antibodies will serve as afoundation for developing bispecific EEVxTfR capable of traversing the blood brain barrier or BBB (phase I extension) and effective ascountermeasures for live EEV exposure in small animal studies (phase II). Antibodies capable of protecting animals from live viral challenge willbe selected for large scale production. Stable high-yield producer mammalian cell lines for affordable large scale antibody production will laythe foundation for subsequent Phase III studies.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government